Nasdaq:PMVPPublished
PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
48% confirmed overall response rate (ORR) with a 10.4-month median duration of response in the primary analysis population of 65 patients with platinum-resistant/refractory ovarian cancer 36% ORR with an 8.1-month median duration of response across all cohorts in the overall…